


Synthetic Carbohydrate Antigens for Immunotherapy Research

TCI offers cancer biomarkers and synthetic antigens

Surgery, radiation, and chemotherapy have been the most common cancer treatments. Recently, antibody-based therapies, antibody stimulating cancer vaccines, immunotherapy, and CAR T-cell therapy has attracted attention. Tumor-associated carbohydrate antigens play an important role in these treatments, which are becoming increasingly mainstream. Here, we introduce oligosaccharide reagents, which represent a new avenue of research and may lead to new therapeutic methods.

Cancer vaccines

Cancer cells have unique antigens, which are potential targets for new therapeutic drugs. In contrast to antibody-based therapies that target molecular changes in malignant cells, cancer vaccines give immune cells the ability to recognize cancer cells by exposing them to cancer antigens. The depletion of the target molecules is the primary issue affecting the drug discovery process, therefore, attention is being focused on carbohydrate antigens.




Carbohydrate antigens: promising cancer vaccines

Easily modified oligosaccharides and oligosaccharide-linked artificial compounds are useful in carbohydrate vaccine research. TCI strongly supports research involving synthetic carbohydrates, which can be easily modified to meet the needs of the researcher.

Immunotherapy (cell transfer therapy)

Therapeutic antibodies and cancer vaccines are based on cancer cell recognition by immune cells, eventually collaborating to destroy cancer cells. In cell transfer therapy, immune cells are removed from the patient's body, engineered to attack cancer cells, and then returned to the body. Research into the application of carbohydrate reagents is also increasing.



Cytotoxic T Lymphocyte (CTL)

Cellular immune responses resulting from cytotoxic T cells, also known as cytotoxic T lymphocytes (CTL), generate effector cells and attack cancer cells. Stimulating lymphocytes with “cancer antigens”, which only exist on cancer cells, will increase the number of CTLs specifically targeting cancer cells. Therapeutic response is also affected if specific CTLs are increased or administered. Currently, there is a global research effort to develop methods to increase specific cell types.


Dendritic cell therapy

Dendritic cells are branched antigen-presenting cells known for their “tree-like” shapes, which have the ability to present antigens to lymphocytes. Cytotoxic T lymphocytes can be induced if cancer antigens are presented to major histocompatibility complex (MHC) molecules on cell surfaces using the antigen-presenting ability of these cells, and this is a promising approach to cancer treatment.

TCI offers a large selection of reagents that can be used for the preparation of carbohydrate compound combinations and carbohydrate-protein combinations in addition to tools for the evaluation of oligosaccharides conjugated to human serum albumin (HSA).

HSA-Oligosaccharide Conjugates : useful tools for evaluating carbohydrate-binding molecules

These are useful tools for evaluating carbohydrate-binding molecules, including antibodies. The recombinant HSA produced in plants does not contain animal-derived components and cannot be contaminated with virus. Additionally, it has the same structure, characteristics, and biological activity as natural HSA. Several sugar-conjugates are available, and it is also possible to manufacture the sugar-conjugates according to customer specifications. For more details on the products and contracts, please contact us.




HSA-Gb₃ [H1718]
 HSA-Lewis X [H1719]
 HSA-Sialyl Lewis X [H1730]

Synthetic Carbohydrate Antigens for Immunotherapy Research


Tumor-associated carbohydrate antigens

Aminoethyl Glycosides, Aminopropyl Glycosides


Gb₃-β-ethylamine [G0402]




SSEA-1-PrNH₂ [S0946]



Globo-H-PrNH₂ [G0447]




Sialyl Lewis X-Lactose Ethylamine [S0923]




Glycosyl Azides


HNK-1 Ethylazide [H1333]




LacDiNAc Dimer Ethylazide [L0237]




Disialylnonasaccharide-β-ethylazide [D4217]




Conjugation reagents




N-Succinimidyl D-Biotin [S0491]



Fluorescein 5-Isothiocyanate (isomer I) [F0026]




5-Hexynoic Acid [H0882]




4,4'-Dithiodibutyric Acid [D1757]


Glyco-conjugates




Neu5Acα(2-6)Galβ(1-4)GlcNAc having a thiol group



A antigen on beads



HNK-1 Biotin-conjugate



Gb₃ FITC-conjugate

Bioconjugation reagents ▶▶▶ <https://bit.ly/2A9V5IN>




Tumor-associated antigens ▶▶▶ <https://bit.ly/35G0H8Y>



Anti-oligosaccharide antibodies ▶▶▶ <https://bit.ly/3b6zRbf>



α -Galactosyl Ceramide (α -GalCer)




α -Galactosyl Ceramide (α -GalCer) is an artificial glycolipid which has been developed based on the sphingolipid extracted from the sea sponge, *Agelas mauritanus*.¹⁻³⁾ Work conducted by Prof. Taniguchi demonstrated that α -GalCer forms a complex with the CD1d antigen present on cell surfaces.^{4,5)} This complexing results in strong NKT (Natural Killer T) cell activation causing high levels of cytokine production.^{6,7)} The NKT cells bare features of both of NK cells and T cells.⁸⁾ Since α -GalCer is related to immune functions, it is used in disease research on cancer, atopic dermatitis and asthma and also is used as an adjuvant for experiment and research. Moreover, a synthetic intermediate of α -GalCer is required in synthetic research of analogs containing different functional groups

such as unsaturation and aromatic groups on the ceramide moiety which can increase biological activity of α -GalCer.⁹⁾ TCI can provide large amount of α -GalCer and its intermediates synthesized in our facilities. Additionally, we can offer highly pure α -GalCer for use as a standard and other applications.

References

- 1) M. Morita et al., *J. Med. Chem.* **1995**, 38, 2176.
- 2) T. Natori et al., *Tetrahedron Lett.* **1993**, 34, 5591.
- 3) T. Natori et al., *Tetrahedron* **1994**, 50, 2771.
- 4) T. Kawano et al., *Science* **1997**, 278, 1626.
- 5) N. Kamada et al., *Int. Immunol.* **2001**, 13, 853.
- 6) M. Taniguchi, *Hyoujun menekigaku (Standard Immunology)*, Igaku-shoin, **2013**, 226.
- 7) M. Taniguchi, M. Harada, et al., *Annu. Rev. Immunol.* **2003**, 21, 48.
- 8) Y. Makino et al., *Int. Immunol.* **1995**, 7, 1157.
- 9) T. Tashiro, K. Mori, *Trends Glycosci. Glycotechnol.* **2010**, 22, 280.



Advantages

- High purity, fully chemically-synthesized product available for scale-up
- We can accept your request of GMP production.

We can create custom product compositions to suit your needs. For more information, please contact us.

Immunostimulant Ingredients ▶▶▶ <https://bit.ly/2WawqfD>



For further information please refer to our website at www.TCIchemicals.com. ▶▶▶



Ordering and Customer Service

TCI AMERICA

Tel : 800-423-8616 / 503-283-1681
Fax : 888-520-1075 / 503-283-1987
E-mail : Sales-US@TCIchemicals.com

TCI EUROPE N.V.

Tel : +32 (0)3 735 07 00
Fax : +32 (0)3 735 07 01
E-mail : Sales-EU@TCIchemicals.com

TCI Deutschland GmbH

Tel : +49 (0)6196 64053-00
Fax : +49 (0)6196 64053-01
E-mail : Sales-DE@TCIchemicals.com

Tokyo Chemical Industry UK Ltd.

Tel : +44 (0)1865 784560
Fax : +44 (0)1865 784561
E-mail : Sales-UK@TCIchemicals.com

TCI Chemicals (India) Pvt. Ltd.

Tel : 1800 425 7889 / 044-2262 0909
Fax : 044-2262 8902
E-mail : Sales-IN@TCIchemicals.com

梯希爱(上海)化成工业发展有限公司

Tel : 800-988-0390 / 021-67121386
Fax : 021-6712-1385
E-mail : Sales-CN@TCIchemicals.com

TOKYO CHEMICAL INDUSTRY CO., LTD.

Tel : +81 (0)3-5640-8878
Fax : +81 (0)3-5640-8902
E-mail : globalbusiness@TCIchemicals.com

Availability, price or specification of the listed products are subject to change without prior notice. Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd.